Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential

Blood

Volumn 121, Issue 18, 2013, Pages 3714-3717

  DeKelver, Russell C ^a   Yan, Ming ^b   Ahn, Eun Young ^b,e   Shia, Wei Jong ^b   Speck, Nancy A ^c   Zhang, Dong Er ^a,b,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AML1 ETO FUSION PROTEIN; HYBRID PROTEIN; MUTANT PROTEIN; NUCLEAR RECEPTOR COREPRESSOR; SON PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; ONCOPROTEIN; RECEPTOR INTERACTING PROTEIN 140; TRANSCRIPTION FACTOR RUNX1;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ATTENUATION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL TRANSFORMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; GENE REPRESSION; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL STRAIN HEK293; CELL STRAIN K 562; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKEMIA; METABOLISM; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DOWN-REGULATION; GENE EXPRESSION REGULATION, LEUKEMIC; HEK293 CELLS; HUMANS; K562 CELLS; LEUKEMIA; MICE; MICE, INBRED C57BL; NUCLEAR RECEPTOR CO-REPRESSOR 1; ONCOGENE PROTEINS, FUSION; PROTEIN BINDING;

MLCS; MLOWN;

EID: 84875472161     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-465641     Document Type: Article

References (25)

1. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood. 1995;86(1):1-14.
2. Langabeer SE, Walker H, Rogers JR, et al. MRC Adult Leukaemia Working Party. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. Br J Haematol. 1997; 99(4):925-928. (Pubitemid 28047161)
3. Rege K, Swansbury GJ, Atra AA, et al; Disease features in acute myeloid leukemia with t(8;21)(q22;q22) Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40(1-2):67-77. (Pubitemid 32124350)
4. Rowe D, Cotterill SJ, Ross FM, et al. Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol. 2000;111(4):1051-1056. (Pubitemid 32104915)
5. Peterson LF, Boyapati A, Ahn EY, et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood. 2007;110(3): 799-805. (Pubitemid 47267414)
6. Müller AM, Duque J, Shizuru JA, Lübbert M. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene. 2008;27(44):5759-5773.
7. Yan M, Burel SA, Peterson LF, et al. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci USA. 2004;101(49): 17186-17191. (Pubitemid 39627795)
8. Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med. 2006;12(8):945-949. (Pubitemid 44175147)
9. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23(24): 4255-4262. (Pubitemid 38758592)
10. Ahn EY, Yan M, Malakhova OA, et al. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci USA. 2008; 105(44):17103-17108.
11. Hörlein AJ, Näär AM, Heinzel T, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor. Nature. 1995;377(6548):397-404.
12. Heinzel T, Lavinsky RM, Mullen TM, et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature. 1997;387(6628):43-48. (Pubitemid 27202643)
13. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA. 1998;95(18): 10860-10865. (Pubitemid 28413159)
14. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18(12): 7185-7191. (Pubitemid 28533038)
15. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol. 1998;18(12):7176-7184. (Pubitemid 28533037)
16. Ahn EY, DeKelver RC, Lo MC, et al. SON controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell. 2011;42(2):185-198.
17. Ahn EE, Higashi T, Yan M, et al. SON regulates GATA-2 through transcriptional control of the miR-23a-27a-24-2 cluster. J Biol Chem. 2013; 288(8):5381-5388.
18. Liu Y, Chen W, Gaudet J, et al. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell. 2007;11(6):483-497. (Pubitemid 46856906)
19. Okumura AJ, Peterson LF, Okumura F, Boyapati A, Zhang DE. t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood. 2008;112(4):1392-1401.
20. Liu Y, Cheney MD, Gaudet JJ, et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell. 2006;9(4):249-260.
21. Amann JM, Nip J, Strom DK, et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol. 2001;21(19):6470-6483. (Pubitemid 32927415)
22. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36(6):624-630. (Pubitemid 38715991)
23. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011; 471(7337):235-239.
24. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471(7337):189-195.
25. Rhoades KL, Hetherington CJ, Harakawa N, et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000;96(6):2108-2115.